Investors
PRESS RELEASES
UPCOMING EVENTS & PRESENTATIONS
8:30 AM EST
Please dial one of the following numbers 15 minutes prior to the start of the call:
United States: +1-866-966-1396
International: +1-631-510-7495
Israel: +972-3-721-7998
Access code: 8998611
8:00 AM EST
The event will feature presentations from RedHill's management team who will provide an overview of the Company's U.S. commercial strategy for launching Talicia® and Aemcolo®. RedHill’s expects to launch Aemcolo® in Q4/19 and Talicia® in Q1/20 with its expanding dedicated sales force.
Management will be available to answer questions at the conclusion of the event.
For further information please contact: investors@redhillbio.com
FEATURED EVENTS
8:00 AM EST
The event will feature presentations from RedHill's management team who will provide an overview of the Company's U.S. commercial strategy for launching Talicia® and Aemcolo®. RedHill’s expects to launch Aemcolo® in Q4/19 and Talicia® in Q1/20 with its expanding dedicated sales force.
Management will be available to answer questions at the conclusion of the event.
For further information please contact: investors@redhillbio.com
An abstract discussing the study’s top-line results, ‘A Phase III Randomized, Double Blind, Placebo-Controlled, Multicenter, Parallel Group Study To Assess The Efficacy And Safety Of Add-On Fixed-Dose Anti-Mycobacterial Therapy (RHB-104) In Moderately To Severely Active Crohn's Disease (MAP US)’ was presented as a late-breaking abstract today at the United European Gastroenterology Week (UEG Week 2018) by Dr. David Y. Graham, M.D., Professor of Medicine, Molecular Virology and Microbiology at Baylor College of Medicine, Houston and Lead Investigator of the MAP US study.